Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1751.44% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.25M.
Undervalued
The company’s latest PE is -12.40, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 67.84M shares, increasing 15.88% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.15M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.42.